Name: Anacetrapib (MK-0859)
Price: 335.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Anacetrapib, also known as MK-0859, is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) that exhibits strong inhibition against CETP-mediated transfer of cholesteryl esters and triglycerides with values of inhibition constant IC50 of 16 nM and 29 nM respectively. Anacetrapib is mainly metabolized by CYP3A4 through O-demethylation, hydroxylation on the biphenyl moiety and hydroxylation on the isopropyl side chain resulting in three oxidative metabolites M1, M2 and M3 respectively. Anacetrapib is being investigated for the treatment of primary hypercholesterolemia and mixed hyperlipidemia due to its impressive effects to lower low-density lipoprotein (LDL) cholesterol levels and increase high-density lipoprotein (HDL) cholesterol levels without any associated major adverse events.
- Properties
  - Alternative Name
    
    MK 0859, MK0859; (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[[2-(4-fluoro-2-methoxy-5-propan-2-ylphenyl)-5-(trifluoromethyl)phenyl]methyl]-4-methyl-1,3-oxazolidin-2-one
    
    CAS Number
    
    875446-37-0
    
    Molecular Formula
    
    C30H25F10NO3
    
    Molecular Weight
    
    637.51
    
    Appearance
    
    A solid
    
    Purity
    
    99.76%
    
    Solubility
    
    ≥31.9 mg/mL in DMSO; insoluble in H2O; ≥86.6 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Lee EY, Yoo JA, et al. "Anti-Aging and Tissue Regeneration Ability of Policosanol Along with Lipid-Lowering Effect in Hyperlipidemic Zebrafish via Enhancement of High-Density Lipoprotein Functionality." Rejuvenation Res. 2016 Apr;19(2):149-58. PMID:26413884

Anacetrapib (MK-0859)

Anacetrapib (MK-0859)

Background

We Also Recommend

Dalcetrapib (JTT-705, RO4607381)

Evacetrapib (LY2484595)

Torcetrapib